The Wistar Institute Cancer Center presents four Type II Shared Resources in this application: Bioinformatics, Genomics, Molecular Screening, and Proteomics. During the past project period the Cancer Center made substantial investments in the Type II Shared Resources, utilizing over $5.5 million in capital funds and equipment grants for equipment upgrades and facility improvements. These Resources function as engines, integrated components ofthe research being conducted by Cancer Center members. The Type II Resources have demonstrated a significant impact to the scientific objectives of the Cancer Center, contributing to 153 of 382 (40%) of the unique cancer-related publications reported by the three scientific Programs. Following a comprehensive realignment of all of its Shared Resources by the appointment of dedicated leadership as described in the Cancer Center Administration section of this application. Shared Resources were grouped as Type I or Type II, reflecting the intensity of collaborative input of their services. Type II Shared Resources provide a higher intensity of collaboration and impact on service, requiring an initial consultation to define the scope of service and remain consultative throughout the service delivery. For many projects. Type II Shared Resources participate in experiment design for sample preparation, services often need to be adapted to address specific scientific problems, and frequently the resulting complex datasets need to be reviewed with the user followed by further data analysis. Regular correspondence and method modifications are required throughout the delivery ofthe service in order to determine the appropriate course of action. Therefore, a distinctive feature of Type II Resources is a substantial amount of individualized, project-driven consultative time and effort provided by Resource staff to users. Accordingly, it is usually impractical for such services to achieve full recovery of operating costs through chargebacks. Clear benchmarks and objective review criteria were introduced in order to enable timely oversight, scientific impact, quality of service, and financial strength for each Shared Resource. Regular evaluations of scientific impact for the Cancer Center (i) and sustainability of services (ii) for each Resource, guide the decision-making process for the Shared Resources. Overall Type II Shared Resources represent clear engines for research as their impact on innovation and discovery is inherent to the individualized nature of their services.

Public Health Relevance

The multidisciplinary nature and extraordinary complexity of modern cancer research require technologically advanced approaches that support refinement of the experimental question, customization of the most appropriate research tool and consultative review of data analysis and interpretation. Type II Shared Resources offer these services to Cancer Center investigators as an integrated and scientifically-driven extension of their research laboratories.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Tempera, Italo; De Leo, Alessandra; Kossenkov, Andrew V et al. (2016) Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol 90:345-55
Nelson, David M; Jaber-Hijazi, Farah; Cole, John J et al. (2016) Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol 17:158
Seo, Jae Ho; Rivadeneira, Dayana B; Caino, M Cecilia et al. (2016) The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. PLoS Biol 14:e1002507
Haut, Larissa H; Gill, Amanda L; Kurupati, Raj K et al. (2016) A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods :
Peck, Barrie; Schug, Zachary T; Zhang, Qifeng et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab 4:6
Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72
Vazquez, Alexei; Kamphorst, Jurre J; Markert, Elke K et al. (2016) Cancer metabolism at a glance. J Cell Sci 129:3367-73
Kumar, Vinit; Patel, Sima; Tcyganov, Evgenii et al. (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol 37:208-20
Kung, Che-Pei; Murphy, Maureen E (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231:R61-R75
Patro, Sean C; Azzoni, Livio; Joseph, Jocelin et al. (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223-31

Showing the most recent 10 out of 582 publications